IHE vs. GERM

Last updated Apr 2, 2026

Compare and contrast key facts about iShares U.S. Pharmaceuticals ETF (IHE) and Amplify Treatments, Testing and Advancements ETF (GERM).

IHE and GERM are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. IHE is a passively managed fund by iShares that tracks the performance of the Dow Jones U.S. Select Pharmaceuticals Index. It was launched on May 5, 2006. GERM is a passively managed fund by Amplify that tracks the performance of the Prime Treatments, Testing and Advancements Index. It was launched on Jun 17, 2020. Both IHE and GERM are passive ETFs, meaning that they are not actively managed but aim to replicate the performance of the underlying index as closely as possible.

Performance

IHE vs. GERM - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in iShares U.S. Pharmaceuticals ETF (IHE) and Amplify Treatments, Testing and Advancements ETF (GERM). The values are adjusted to include any dividend payments, if applicable.

IHE vs. GERM - Yearly Performance Comparison

	2026 (YTD)	2025	2024
IHE iShares U.S. Pharmaceuticals ETF	3.70%	31.69%	-6.49%
GERM Amplify Treatments, Testing and Advancements ETF	0.00%	0.00%	0.00%

Returns By Period

IHE

• 1D: 1.15%
• 1M: -3.66%
• YTD: 3.70%
• 6M: 18.16%
• 1Y: 32.13%
• 3Y*: 16.43%
• 5Y*: 10.17%
• 10Y*: 8.20%

GERM

• 1D: 0.00%
• 1M: 0.00%
• YTD: 0.00%
• 6M: 0.00%
• 1Y: 0.00%
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

IHE vs. GERM - Expense Ratio Comparison

IHE has a 0.42% expense ratio, which is lower than GERM's 0.68% expense ratio.

GERM

Amplify Treatments, Testing and Advancements ETF

IHE

iShares U.S. Pharmaceuticals ETF

Return for Risk

IHE vs. GERM — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

IHE

IHE Risk / Return Rank: 78
IHE Sharpe Ratio Rank: 81
IHE Sortino Ratio Rank: 81
IHE Omega Ratio Rank: 75
IHE Calmar Ratio Rank: 83
IHE Martin Ratio Rank: 72

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

IHE vs. GERM - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for iShares U.S. Pharmaceuticals ETF (IHE) and Amplify Treatments, Testing and Advancements ETF (GERM). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	IHE	GERM	Difference
Sharpe ratio Return per unit of total volatility	1.59	—	—
Sortino ratio Return per unit of downside risk	2.20	—	—
Omega ratio Gain probability vs. loss probability	1.29	—	—
Calmar ratio Return relative to maximum drawdown	2.52	—	—
Martin ratio Return relative to average drawdown	7.93	—	—
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

Sharpe Ratios by Period

	IHE	GERM	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.59	—	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.64	—	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.45	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.50	—	—

Dividends

IHE vs. GERM - Dividend Comparison

IHE's dividend yield for the trailing twelve months is around 1.70%, while GERM has not paid dividends to shareholders.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
IHE iShares U.S. Pharmaceuticals ETF	1.70%	1.76%	1.73%	1.39%	2.01%	1.49%	1.19%	1.40%	1.25%	1.36%	0.92%	1.93%
GERM Amplify Treatments, Testing and Advancements ETF	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Drawdowns

IHE vs. GERM - Drawdown Comparison

The maximum IHE drawdown since its inception was -38.20%, which is greater than GERM's maximum drawdown of 0.00%. Use the drawdown chart below to compare losses from any high point for IHE and GERM.

Drawdown Indicators

	IHE	GERM	Difference
Max Drawdown Largest peak-to-trough decline	-38.20%	0.00%	-38.20%
Max Drawdown (1Y) Largest decline over 1 year	-10.58%	0.00%	-10.58%
Max Drawdown (5Y) Largest decline over 5 years	-16.03%	—	—
Max Drawdown (10Y) Largest decline over 10 years	-29.59%	—	—
Current Drawdown Current decline from peak	-4.22%	0.00%	-4.22%
Average Drawdown Average peak-to-trough decline	-7.95%	0.00%	-7.95%
Ulcer Index Depth and duration of drawdowns from previous peaks	3.36%	0.00%	+3.36%

Volatility

IHE vs. GERM - Volatility Comparison

iShares U.S. Pharmaceuticals ETF (IHE) has a higher volatility of 5.91% compared to Amplify Treatments, Testing and Advancements ETF (GERM) at 0.00%. This indicates that IHE's price experiences larger fluctuations and is considered to be riskier than GERM based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	IHE	GERM	Difference
Volatility (1M) Calculated over the trailing 1-month period	5.91%	0.00%	+5.91%
Volatility (6M) Calculated over the trailing 6-month period	12.12%	0.00%	+12.12%
Volatility (1Y) Calculated over the trailing 1-year period	20.70%	0.00%	+20.70%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	15.95%	0.00%	+15.95%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	18.11%	0.00%	+18.11%